Statins Antihyperlipidemics Anticancer Agents
Statins Antihyperlipidemics Anticancer Agents
Statins are a class of compounds widely used for their antihyperlipidemic activity, clinically prescribed to lower plasma levels of low-density lipoprotein (LDL) and total cholesterol. Their primary mechanism of action is the inhibition of HMG-CoA reductase, a key enzyme in cholesterol biosynthesis, which in turn reduces production of the cholesterol precursor mevalonate.
Beyond lipid lowering, statins also suppress the synthesis of prenylated proteins, leading to secondary benefits such as improved endothelial function, modulation of inflammatory responses, and enhanced cardiovascular health.
Statins are generally divided into two groups:
• Fungal-derived metabolites and their analogs
· Mevinolin (M125960 ≥98%, M407862 10mM in DMSO)
· Simvastatin (S129538 ≥97%, S407772 10mM in DMSO)
· Pravastatin Sodium (P579658 ≥99%, P107388 ≥98%, P407896 10mM in DMSO )
• Fully synthetic statins
· Atorvastatin Calcium Trihydrate (A179410 ≥97%)
· Fluvastatin Sodium (F129852 ≥98%, F408261 10mM in DMSO)
· Rosuvastatin Calcium (R129220 ≥99%, R408257 10mM in DMSO)
In addition to their cardiovascular benefits, statins have demonstrated anticancer activity in both cellular and animal models.
• In myeloid leukemia and medulloblastoma cells, Lovastatin induces G1-phase cell cycle arrest and apoptosis, resulting in reduced proliferation.
• In animal models, lovastatin shows anti-angiogenic effects, suppressing VEGF secretion and inhibiting tumor-associated blood vessel formation.
• Other studies indicate that Rosuvastatin and Fluvastatin inhibit Ras protein translocation, thereby limiting pancreatic tumor growth in vivo.
Also Available products from Aladdin:
C275025 Cerivastatin Sodium
F129852 F408261 Fluvastatin Sodium
L107708 L107709 L408097 Lovastatin
P129617 P421721 Pitavastatin Calcium
P107388 P579658 P407896 Pravastatin Sodium
P274681 Pravastatin Lactone
R129220 R408257 Rosuvastatin Calcium
References:
1. Blumenthal RS. Am Heart J. 2000 Apr;139(4):577-83.
2. Krause BR, Newton RS. Atherosclerosis. 1995 Oct;117(2):237-44.
3. Spindler SR, Li R, Dhahbi JM, et al. PLoS One. 2012;7(6):e39581.
4. Furberg CD. Circulation. 1999 Jul 20;100(3):e14-7.
5. Kostner GM. Wien Med Wochenschr. 1999;149(5-6):120-4.
6. Bergstrom JD, Bostedor RG, Rew DJ, et al. Biochim Biophys Acta. 1998 Jan 23;1389(3):213-21.
7. Thurnher M, Nussbaumer O, Gruenbacher G. Clin Cancer Res. 2012 Jul 1;18(13):3524-31.
8. Park WH, Lee YY, Kim ES, et al. Anticancer Res. 1999 Jul-Aug;19(4B):3133-40.
9. Macaulay RJ, Wang W, Dimitroulakos J, et al. J Neurooncol. 1999 Mar;42(1):1-11.
10. Feleszko W, Balkowiec EZ, Sieberth E, et al. Int J Cancer. 1999 May 17;81(4):560-7.
11.Gbelcová H, Lenícek M, Zelenka J, et al. Int J Cancer. 2008 Mar 15;122(6):1214-21.
Aladdin: https://www.aladdinsci.com/